CytoSorbents
≡
  • Home
  • About
    • About Us
    • Board
    • Executive Management
    • Advisors
    • Our Partners
    • Intellectual Property
  • Products
    • CytoSorb
    • HemoDefend
    • ECOS-300CY
    • DrugSorb-ATR
    • VetResQ
  • Technology
    • Power of the Bead
    • Product Pipeline
    • Focus: CytoSorb-XL
    • Focus: Kontrol
  • Investor Relations
    • Overview
    • Events & Presentations
    • Analyst Coverage
    • Financial Results
    • Videos
    • SEC Filings
    • Stock Quote
    • Investor FAQ
    • Corporate Governance
  • News
    • Press Releases
    • Publications
    • White Papers
    • Press Kit
    • Media
  • Contact
    • Contact Us
    • Become A Partner
    • Career Opportunities

Press Releases

2022
May
  • CytoSorbents to Present at Two Upcoming Investor Conferences

    May 19, 2022
  • CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook

    May 3, 2022
  • CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany

    May 2, 2022
April
  • First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery

    April 29, 2022
  • CytoSorbents Highlights the Strategy of “Enhanced Lung Rest” Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress

    April 28, 2022
  • CytoSorbents to Report First Quarter 2022 Operating and Financial Results

    April 19, 2022
  • CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World

    April 14, 2022
  • CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program

    April 7, 2022
  • CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors

    April 5, 2022
March
  • CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM)

    March 17, 2022
  • CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook

    March 8, 2022
February 2022
  • CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results

    February 8, 2022
  • CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences

    February 3, 2022
  • First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock

    February 1, 2022
January 2022
  • New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents’ Antithrombotic Drug Removal Technology

    January 24, 2022
  • CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

    January 18, 2022
2021
December 2021
  • CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular

    December 21, 2021
  • CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

    December 20, 2021
Novemmber 2021
  • CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference

    November 15, 2021
  • CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results

    November 4, 2021
October 2021
  • CytoSorbents Comments on REMOVE Study Presentation

    October 20, 2021
  • First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery

    October 14, 2021
  • CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery

    October 12, 2021
  • CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance

  • CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference

    October 7, 2021
September
  • CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19

    September 14, 2021
  • CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships and Studies

    September 13, 2021
  • CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery

    September 10, 2021
  • CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

    September 8, 2021
  • Topline Results from CytoSorbents’ U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

    September 1, 2021
August
  • CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress

    August 30, 2021
  • Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents’ DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery

    August 12, 2021
  • CytoSorbents Reports Second Quarter 2021 Financial and Operational Results

    August 3, 2021
July
  • CytoSorbents Completes its Mission 100,000 International Fundraising Campaign to Fight the Spread of COVID-19 for Global Humanitarian Organization, CARE

    July 30, 2021
  • CytoSorbents to Report Second Quarter 2021 Operating and Financial Results

    July 19, 2021
  • CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery

    July 6, 2021
June
  • CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications

    June 1, 2021
May
  • CytoSorbents to Present at the Jefferies Virtual Healthcare Conference

    May 27, 2021
  • CytoSorb® Registered and Commercially Available in Singapore

    May 25, 2021
  • CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit

    May 19, 2021
  • CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic Injury

    May 11, 2021
  • CytoSorbents Reports First Quarter 2021 Financial and Operational Results

    May 4, 2021
April
  • CytoSorbents to Report Q1 2021 Operating and Financial Results

    April 27, 2021
  • U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery

    April 19, 2021
March
  • CytoSorbents Announces Lease of New Global Headquarters in Princeton, New Jersey

    March 29, 2021
  • CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardiothoracic Surgery

    March 16, 2021
  • CytoSorbents to Present at the Oppenheimer 31st Annual Healthcare Conference

    March 12, 2021
  • CytoSorbents Announces 2020 Financial and Operational Results

    March 9, 2021
  • B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®

    March 2, 2021
  • CytoSorbents to Report Fiscal 2020 Operating and Financial Results

    March 1, 2021
February
  • CytoSorbents to Present at the Cowen 41st Annual Health Care Conference

    February 24, 2021
  • CytoSorbents 2021: Leadership and Growth in the “New Normal”

    February 18, 2021
  • CytoSorbents to Present at the 10th Annual SVB Leerink Global Healthcare Conference

    February 16, 2021
  • National Institute for Health and Care Excellence (NICE) Issues Medtech Innovation Briefing on CytoSorb for Reducing Risk of Bleeding During Cardiac Surgery

    February 4, 2021
January
  • CytoSorbents Appoints David D. Cox, PhD, MBA as Vice President – Global Regulatory Affairs

    January 21, 2021
  • CytoSorbents Announces Approval of CytoSorb® in Korea in Collaboration with Partner Fresenius Medical Care

    January 19, 2021
  • Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients

    January 12, 2021
  • CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue

  • CytoSorbents Appoints James Komsa as Vice President – U.S. Sales and Marketing

    January 11, 2021
  • Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients

    January 4, 2021
2020
December
  • CytoSorbents Promotes Dr. Christian Steiner to Executive Vice President of Sales and Marketing

    December 17, 2020
  • CytoSorbents Pays Off $15M Term Loans and Establishes New Undrawn $15M Loan Commitment with Bridge Bank

    December 10, 2020
  • Early CytoSorb Initiation Improves Hemodynamic Stabilization and Survival in New Septic Shock Study

    December 9, 2020
  • CytoSorbents Launches International Campaign to Raise $100,000 for the Global Humanitarian Organization, CARE

    December 2, 2020
November
  • CytoSorbents Highlights Largest Published Case Series To Date Using CytoSorb in Critically Ill COVID-19 Patients

    November 25, 2020
  • CytoSorbents to Present at the Piper Sandler 32nd Annual Healthcare Conference

    November 23, 2020
  • CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference

    November 12, 2020
  • CytoSorbents Reports Record Third Quarter 2020 Financial Results

    November 4, 2020
October
  • CytoSorbents to Report Q3 2020 Operating and Financial Results

    October 21, 2020
  • CytoSorbents and Aferetica Announce European Union Approval of the PerLife™ System and ECOS-300CY™ PerSorb™ Cartridge for Combined Perfusion and Purification of Solid Organs Dedicated to Transplant

    October 14, 2020
  • The U.S. Department of Defense Awards $1.1 Million to CytoSorbents to Optimize Development of HemoDefend-BGA™ for Life-saving Universal Plasma

    October 9, 2020
September
  • CytoSorb Achieves Registration in Brazil and Is Now Commercially Available To Treat Cytokine Storm in COVID-19 Infection and Other Conditions

    September 21, 2020
  • CytoSorbents Highlights CytoSorb Use in Sepsis Patients During Sepsis Awareness Month and World Sepsis Day 2020

    September 11, 2020
  • CytoSorbents Announces the “CytoSorb Therapy in COVID-19 ICU Patients” (CTC) Registry Is Actively Enrolling

    September 8, 2020
August
  • Terumo Cardiovascular and CytoSorbents Collaborate to Commercialize CytoSorb® in Ten U.S. Hotspot States under Emergency Use Authorization for COVID-19

    August 24, 2020
  • CytoSorbents Partners with InvoSurg and Surgical Partners to Commercialize CytoSorb® in the U.S. Northeast, Mid-Atlantic, and Florida under FDA Emergency Use Authorization for COVID-19

    August 17, 2020
  • CytoSorbents Reports Record Second Quarter 2020 Financial Results

    August 4, 2020
  • CytoSorbents Achieves Milestone of More than 100,000 CytoSorb Treatments Delivered Cumulatively To Date

    August 3, 2020
July
  • CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development

    July 31, 2020
  • CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data

    July 28, 2020
  • CytoSorbents to Report Q2 2020 Operating and Financial Results

  • CytoSorbents Corporation Announces Pricing of $50 Million Public Offering of Common Stock

    July 22, 2020
  • CytoSorbents Provides Preliminary Q2 2020 Financial Results and Corporate Update

    July 20, 2020
  • CytoSorbents Corporation Announces Proposed $40 Million Public Offering of Common Stock

  • C O R R E C T I O N — CytoSorbents Corporation

    July 8, 2020
June
  • CytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients at Risk of Bleeding

    June 29, 2020
  • CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise

    June 24, 2020
  • CytoSorbents Awarded $2,897,172 Phase III STTR Contract to Advance HemoDefend-BGA Plasma and Whole Blood Filter to Clinical Trials

    June 9, 2020
May
  • CytoSorbents Announces Virtual Annual Meeting

    May 27, 2020
  • CytoSorb® is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery

    May 12, 2020
  • CytoSorbents Reports First Quarter 2020 Financial and Operational Results

    May 5, 2020
  • CytoSorbents Promotes Vincent J. Capponi to President

    May 4, 2020
April
  • CytoSorbents Receives $1.1 Million in Non-Dilutive Funding from the New Jersey Business Tax Certificate Transfer Program

    April 29, 2020
  • CytoSorbents to Report Q1 2020 Operating and Financial Results

    April 28, 2020
  • Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer

    April 27, 2020
  • Development Update: U.S. FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery

    April 20, 2020
  • New Study Suggests CytoSorb Improves Clinical Outcomes in Pneumonia Patients With Septic Shock and Acute Respiratory Distress Syndrome (ARDS) on ECMO

    April 15, 2020
  • U.S. FDA Grants CytoSorb® Emergency Use Authorization for Use in Patients with COVID-19 Infection

    April 13, 2020
  • CytoSorbents CEO to Discuss COVID-19 Pandemic and its CytoSorb® Treatment of Cytokine Storm in Cowen COVID-19 Series Conference Call Today

    April 3, 2020
March
  • CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care

    March 31, 2020
  • CytoSorb® Used to Treat More than 70 Critically-Ill COVID-19 Patients and Specifically Added to Coronavirus Treatment Guidelines in Italy and Panama

    March 25, 2020
  • CytoSorbents Provides Update on CytoSorb and COVID-19 Coronavirus Activities

    March 12, 2020
  • CytoSorbents Announces 2019 Financial and Operational Results

    March 5, 2020
  • CytoSorbents Highlights Recent Publication Using CytoSorb during Cardiac Surgery for Infective Endocarditits

    March 2, 2020
February
  • CytoSorbents Enters Agreement with China Medical System Holdings Limited to Bring CytoSorb to Mainland China to Treat Critically-ill Patients with COVID-19 Coronavirus Infection

    February 19, 2020
  • CytoSorb Used Successfully to Help Treat Grade 4 Cytokine Release Syndrome Following CAR T-cell Immunotherapy in First Published Case Report

    February 5, 2020
January
  • CytoSorb® is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.

    January 29, 2020
  • CytoSorb, the Wuhan Coronavirus, and Cytokine Storm

    January 28, 2020
  • CytoSorb Treatment Improves Rat Survival Following Lethal Intravenous Dose of Fungal Aflatoxin

    January 22, 2020
  • CytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter

    January 14, 2020
  • CytoSorbents to Present at Biotech Showcase™ 2020

    January 7, 2020
2019
December
  • CytoSorbents to Present at the Piper Jaffray 31st Annual Healthcare Conference

    December 2, 2019
November
  • CytoSorbents Changes Contract Research Organizations and Temporarily Pauses Enrollment in REFRESH 2-AKI Study

    November 25, 2019
  • CytoSorbents to Present at the Three Part Advisors 2019 Southwest IDEAS Investor Conference

    November 19, 2019
  • Dr. Eric Mortensen to Leave CytoSorbents At Year End

    November 6, 2019
  • CytoSorbents Reports Third Quarter 2019 Financial Results

    November 5, 2019
  • CytoSorbents Announces Additions to its International Clinical Team

    November 4, 2019
  • CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom

    November 1, 2019
October
  • CytoSorbents to Report Q3 2019 Operating and Financial Results

    October 30, 2019
  • CytoSorbents Awarded Approximately $3.0 Million by the U.S. Air Force to Advance Development of the K+ontrol System to Treat Severe Hyperkalemia

    October 22, 2019
  • CytoSorbents to Present at The MicroCap Rodeo Investor Conference

    October 10, 2019
  • CytoSorb® Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac Surgery

    October 4, 2019
  • CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery

    October 2, 2019
September
  • CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock

    September 25, 2019
  • First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence

    September 16, 2019
  • World Sepsis Day 2019: CytoSorbents Highlights Its Support of Multiple Organizations In the Fight Against Sepsis

    September 13, 2019
  • CytoSorbents to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    September 9, 2019
August
  • CytoSorbents Highlights Recent Published Studies on CytoSorb

    August 28, 2019
  • CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022

    August 15, 2019
  • CytoSorbents Expands CytoSorb Distribution in Latin America to Brazil, Colombia, and Costa Rica

    August 13, 2019
  • CytoSorbents Reports Record Second Quarter 2019 Financial Results

    August 6, 2019
  • CytoSorbents Announces Amendment to Loan Agreement with Bridge Bank, Receives an Additional $5 Million Cash from New Term Loan

    August 5, 2019
July
  • CytoSorbents to Report Q2 2019 Operating and Financial Results

    July 30, 2019
June
  • CytoSorbents to Present at the Raymond James Life Sciences and MedTech Conference

    June 18, 2019
  • CytoSorbents to Present at the Three Part Advisors 2019 East Coast IDEAS Investor Conference

    June 11, 2019
  • CytoSorbents to Present at the Jefferies 2019 Global Healthcare Conference

    June 3, 2019
May
  • CytoSorbents to Participate at the B. Riley FBR 20th Annual Institutional Investor Conference

    May 20, 2019
  • CytoSorbents Reports First Quarter 2019 Financial Results and Provides Second Quarter 2019 Guidance

    May 7, 2019
  • CytoSorbents to Report Q1 2019 Operating and Financial Results

    May 1, 2019
April
  • CytoSorbents Highlights the 6th International CytoSorb Users’ Meeting and Recent Activities at the 2019 ISICEM and EuroELSO Conferences

    April 24, 2019
  • CytoSorbents to Present at the H.C. Wainwright Global Life Sciences Conference 2019 London

    April 8, 2019
March
  • CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018

    March 7, 2019
  • CytoSorbents to Present at the Cowen 39th Annual Health Care Conference

    March 6, 2019
  • CytoSorbents Expands Direct Sales to Poland, the Nordics, and the Netherlands

    March 5, 2019
February
  • CytoSorbents to Report Fiscal 2018 Operating and Financial Results

    February 28, 2019
  • CytoSorbents to Participate at the 8th Annual SVB Leerink Global Healthcare Conference

    February 25, 2019
  • CytoSorbents to Present at the 21st Annual BIO CEO & Investor Conference

    February 5, 2019
  • CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial

    February 4, 2019
January
  • CytoSorbents Announces Expansion of CytoSorb® Partnership with Fresenius Medical Care

    January 22, 2019
  • CytoSorbents Issues Stockholder Letter with Preliminary 2018 Financial Results

    January 7, 2019
  • CytoSorbents To Highlight Progress at Biotech Showcase 2019

    January 4, 2019
2018
December
  • CytoSorbents To Receive $619,546 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program

    December 21, 2018
November
  • CytoSorbents to Present at the 30th Annual Piper Jaffray Healthcare Conference

    November 26, 2018
  • CytoSorbents Recognized Again as One of the Fastest Growing Companies in North America on Deloitte’s 2018 Technology Fast 500™

    November 19, 2018
  • CytoSorbents to Present at the Stifel, Jefferies, and Canaccord Investor Conferences This Week

    November 12, 2018
  • CytoSorbents Reports Third Quarter 2018 Financial Results

    November 6, 2018
October
  • CytoSorbents to Report Q3 2018 Operating and Financial Results

    October 31, 2018
  • CytoSorbents to Showcase CytoSorb® at Two Key European Medical Conferences

    October 18, 2018
  • CytoSorbents to Present at the Cantor Fitzgerald Global Healthcare Conference

    October 3, 2018
September
  • CytoSorb® Assigned Dedicated Procedure Code in Switzerland

    September 20, 2018
  • World Sepsis Day 2018: CytoSorbents Sponsors the Sepsis Heroes Gala and the Roger Bone Award for Excellence in Sepsis Research

    September 13, 2018
  • CytoSorbents REFRESH 2-AKI Protocol Amendment Approved by FDA

    September 4, 2018
August
  • CytoSorbents to Present at the B. Riley FBR Healthcare Conference and the H.C. Wainwright 20th Annual Global Investment Conference

    August 28, 2018
  • CytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend™ Blood Transfusion Filter

    August 21, 2018
  • CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018

    August 2, 2018
July
  • CytoSorbents Expands Distribution of CytoSorb® to a Total of 53 Countries Worldwide

    July 31, 2018
  • CytoSorbents to Report Q2 2018 Operating and Financial Results

    July 26, 2018
  • Aferetica and CytoSorbents Debut the PerLife™ System for Organ Preservation and Rehabilitation at the 27th International Congress of the Transplantation Society

    July 9, 2018
June
  • CytoSorbents Added to the Russell 2000 and Russell 3000 Indexes

    June 26, 2018
  • CytoSorbents Officially Opens New U.S. CytoSorb Manufacturing Facility

    June 12, 2018
  • CytoSorbents to Present at the Jefferies 2018 Global Healthcare Conference

    June 4, 2018
May
  • CytoSorbents to Present at the 19th Annual B. Riley FBR Investor Conference

    May 21, 2018
  • CytoSorb® Adds Bilirubin and Myoglobin Reduction to European Union Approved Indications for Use

    May 14, 2018
  • CytoSorbents Reports Strong First Quarter 2018 Financial Results

    May 8, 2018
  • CytoSorbents to Report Q1 2018 Operating and Financial Results

    May 2, 2018
April
  • CytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac Surgery

    April 24, 2018
  • CytoSorbents to Meet With European Investors at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo and in Meetings in Frankfurt, Geneva and Zurich

    April 9, 2018
  • CytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank

    April 4, 2018
March
  • CytoSorbents Reports on the Successful 5th International CytoSorb Users Meeting and 38th ISICEM Critical Care Conference

    March 28, 2018
  • CytoSorbents to Present at the 38th Annual Cowen Healthcare Conference

    March 12, 2018
  • CytoSorbents Achieves Record Revenue and Product Sales Growth in 2017

    March 8, 2018
  • CytoSorbents to Report Fiscal 2017 Operating and Financial Results

    March 1, 2018
February
  • CytoSorbents to Participate at the BTIG Healthcare Conference

    February 26, 2018
  • CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia

    February 15, 2018
  • CytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference

    February 6, 2018
  • New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood Purification

    February 1, 2018
January
  • CytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter

    January 8, 2018
  • CytoSorbents To Provide Corporate Update at Biotech Showcase 2018

    January 3, 2018
2017
December
  • CytoSorbents Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application

    December 21, 2017
  • CytoSorbents Receives $676,739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program

    December 19, 2017
  • German Federal Ministry of Education and Research to Fund the CytoSorb® Endocarditis REMOVE Trial

    December 11, 2017
November
  • CytoSorbents to Present at the LD Micro Main Event Investor Conference 2017

    November 29, 2017
  • CytoSorbents Continues Strong Trajectory of Growth in the Third Quarter 2017

    November 9, 2017
  • CytoSorbents Recognized on Deloitte’s 2017 Technology Fast 500™ as One of the Fastest Growing Companies in North America

  • CytoSorbents to Report Q3 2017 Operating and Financial Results

    November 2, 2017
  • CytoSorbents Awarded Approximately $1.0 Million in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe Hyperkalemia

    November 1, 2017
October
  • CytoSorb® Usage During Valve Replacement Surgery for Infective Endocarditis Helps Stabilize Patients and May Improve Survival

    October 19, 2017
  • CytoSorbents to Present at the 2017 BIO Investor Forum

    October 10, 2017
September
  • CytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine Congress

    September 26, 2017
  • Key Clinical Study Showing Reversal of Refractory Septic Shock in Patients Treated with CytoSorb®

    September 25, 2017
  • World Sepsis Day 2017: CytoSorbents Sponsors the Sepsis Update 2017 Congress and Sepsis Heroes Ceremony

    September 14, 2017
  • Aferetica and CytoSorbents Partner to Enhance the Success of Solid Organ Transplantation

    September 11, 2017
  • CytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference

    September 6, 2017
  • CytoSorbents Highlights Important Research Advances in Traumatic Brain Injury, Hemorrhagic Shock, and Severe Hyperkalemia at the Military Health System Research Symposium

    September 5, 2017
August
  • CytoSorbents Awarded $719,000 Grant To Acutely Stabilize Severe Burn Patients

    August 14, 2017
  • CytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017

    August 7, 2017
  • CytoSorbents to Report Q2 2017 Operating and Financial Results

    August 1, 2017
July
  • CytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR

    July 17, 2017
  • CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma

    July 13, 2017
  • CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank

    July 5, 2017
June
  • CytoSorbents Announces Director and Management Open Market Stock Purchases

    June 15, 2017
  • CytoSorbents – A Leader in Blood Purification to Treat Deadly Inflammation – Teams with Investor Relations Firm LifeSci Advisors

    June 6, 2017
May
  • Dr. Eric R. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer

    May 30, 2017
  • CytoSorbents Selected to Present at Special Operations SOMSA 2017 Conference and 18th Annual B. Riley & Co. Investor Conference

    May 24, 2017
  • Aferetica and CytoSorbents Extend Exclusive “Life-saving” Partnership through 2021

    May 22, 2017
  • CytoSorbents Reports First Quarter 2017 Financial Results

    May 8, 2017
  • CytoSorbents Announces Positive REFRESH I Trial Results

    May 5, 2017
  • CytoSorbents to Report Q1 2017 Operating and Financial Results

    May 2, 2017
April
  • CytoSorbents Awarded $1M Phase II SBIR Contract by U.S. Department of Defense to Advance Fungal Mycotoxin Blood Purification

    April 24, 2017
  • CytoSorbents 2017 – Propelling the Company to the “Next Level”

    April 19, 2017
March
  • CytoSorbents Announces Pricing of Follow-On Offering

    March 31, 2017
  • CytoSorbents Announces Proposed Offering of Common Stock

    March 30, 2017
  • CytoSorbents Strengthens Intellectual Property Portfolio with New Patents Issued in the U.S., China, Japan, Russia, and Australia

    March 28, 2017
  • CytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference

    March 27, 2017
  • Dr. Carl H. June, Cancer Immunotherapy Pioneer, Joins CytoSorbents Scientific Advisory Board

    March 22, 2017
  • CytoSorb® Treatment of HLH – The Parallel to Cytokine Release Syndrome in Cancer Immunotherapy

    March 20, 2017
  • CytoSorbents Announces CytoSorb® Partnership with Dr. Reddy’s Laboratories

    March 16, 2017
  • CytoSorbents Highlights Activities at the 22nd International Conference on Advances in Critical Care Nephrology

    March 7, 2017
  • CytoSorbents to Present at the Maxim Group – Haitong Securities Inaugural Healthcare Investor and Partnering Conference

    March 6, 2017
  • CytoSorbents Reports Record Quarterly and Full-Year 2016 Revenue

    March 3, 2017
  • CytoSorbents to Present at 37th Annual Cowen and Company Healthcare Conference

    March 2, 2017
February
  • CytoSorbents to Report Fiscal 2016 Operating and Financial Results

    February 24, 2017
  • CytoSorbents to Present at the 19th Annual BIO CEO & Investor Conference

    February 7, 2017
January
  • CytoSorbents Launches VetResQ™ for U.S. Veterinary Market

    January 20, 2017
  • CytoSorbents Pre-announces Q4 2016 and Full-Year 2016 Results

    January 10, 2017
  • Fresenius Medical Care and CytoSorbents Expand Original Partnership and Add New Co-Marketing Agreement for Worldwide CytoSorb® Markets

    January 9, 2017
  • CytoSorbents To Provide Corporate Update at Biotech Showcase 2017

    January 3, 2017
2016
December
  • CytoSorbents Announces First Sales of New CytoSorb® CPB Procedure Pack for Cardiac Surgery

    December 20, 2016
  • CytoSorbents Receives $318,551 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program

    December 12, 2016
  • CytoSorb® Attains Permanent, Dedicated Reimbursement Code in Core Market of Germany Expected to Catalyze Major Increases in Adoption and Sales of CytoSorb® in Germany

    December 7, 2016
  • CytoSorbents to Present at the LD Micro Main Event Investor Conference

    December 2, 2016
  • CytoSorb® Selected for NICE MedTech Innovation Briefing in the United Kingdom

    December 1, 2016
November
  • First Successful Treatment of Dengue Fever and Dengue Shock Syndrome Using CytoSorb®

    November 22, 2016
  • CytoSorbents Reports Highlights from the SepsEast 2016 Critical Care Congress

    November 17, 2016
  • Adrian Thomas Joins CytoSorbents to Drive Western European Sales

    November 15, 2016
  • CytoSorb® Q3 2016 Sales Reach Record $2.14M, Doubling From a Year Ago

    November 7, 2016
  • CytoSorbents Expands Direct Sales of CytoSorb to Belgium and Luxembourg

    November 3, 2016
  • CytoSorbents to Report Q3 2016 Operating and Financial Results

    November 1, 2016
October
  • CytoSorbents Congratulates Kathleen Bloch as NJBIZ Public Company Chief Financial Officer of the Year

    October 17, 2016
  • CytoSorbents to Present at the 2016 BIO Investor Forum

    October 14, 2016
  • CytoSorbents and Foxx Medical Begin Saving Lives in Chile with CytoSorb®

    October 11, 2016
  • CytoSorbents Announces Positive Top-line Safety Data from REFRESH I Cardiac Surgery Trial

    October 5, 2016
  • International Marketing of CytoSorb® Commences at European Association for Cardio-Thoracic Surgery Conference

    October 3, 2016
September
  • New CytoSorbents Website Highlights Global Growth and Innovation

    September 29, 2016
  • CytoSorbents Expands CytoSorb® into Iran with Partner Arsak

    September 23, 2016
  • CytoSorbents Sponsors Sepsis Heroes Gala in Honor of World Sepsis Day

    September 15, 2016
  • Terumo Cardiovascular Group and CytoSorbents Announce CytoSorb Cardiac Surgery Partnership

    September 12, 2016
  • CytoSorbents Advances War On Sepsis with Development of CytoSorb-XL

    September 8, 2016
  • CytoSorbents to Present at the 2016 Rodman & Renshaw Annual Global Investment Conference

    September 7, 2016
August
  • CytoSorbents Achieves Fourth Consecutive Quarter of Record CytoSorb® Sales

    August 9, 2016
  • CytoSorbents Awarded $650,000 in SBIR Grant Contracts to Continue Development of Novel Hemocompatible Potassium Binding Polymers

    August 8, 2016
  • CytoSorbents to Report Q2 2016 Operating and Financial Results

    August 2, 2016
July
  • CytoSorbents Teams with Medial and Meditrade to Bring CytoSorb® to Hungary, Czech Republic, Slovakia, and Poland

    July 13, 2016
  • CytoSorbents to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference

    July 6, 2016
  • CytoSorbents Closes $10 Million Debt Financing with Bridge Bank

    July 1, 2016
June
  • CytoSorbents Awarded $150,000 Phase I STTR Contract for Universal Plasma Development

    June 22, 2016
  • CytoSorbents and Palex Bring CytoSorb® to Spain and Portugal

    June 13, 2016
  • CytoSorbents Announces Fresenius Medical Care Initiates Sales of CytoSorb® in France, Poland and Scandinavia

    June 1, 2016
May
  • Independent Data Safety Monitoring Board Recommends Continuation of CytoSorbents REFRESH I Trial

    May 27, 2016
  • CytoSorb® Achieves Final Product Registration in Russia

    May 18, 2016
  • CytoSorbents Continues Strong Growth in Q1 2016

    May 9, 2016
  • CytoSorbents Establishes Swiss Subsidiary

    May 6, 2016
  • CytoSorbents to Report Q1 2016 Operating and Financial Results

    May 2, 2016
April
  • CytoSorbents To Present At The 15th Annual Needham Healthcare Conference

    April 6, 2016
March
  • CytoSorbents Awarded $150,000 Phase I SBIR Contract for Fungal Mycotoxin Removal

    March 25, 2016
  • CytoSorbents Reports on Successful 3rd International CytoSorb® Users Meeting

    March 16, 2016
  • CytoSorbents to Host 3rd International CytoSorb® Users Meeting and ISICEM 2016 Symposium

    March 14, 2016
  • CytoSorbents Reports Record Quarterly and Full-Year 2015 Revenue

    March 9, 2016
  • CytoSorbents to Report Fiscal 2015 Operating and Financial Results

    March 2, 2016
February
  • Data Presented on First CytoSorb® Investigator-Initiated Septic Shock Study

    February 26, 2016
  • CytoSorbents to Exhibit at the 45th Society of Critical Care Medicine Congress

    February 18, 2016
  • CytoSorbents Announces 26th Symposium for Intensive Medicine and Intensive Care Agenda in Bremen, Germany

    February 16, 2016
  • CytoSorbents to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference

    February 4, 2016
  • CytoSorbents Receives $325,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program

    February 1, 2016
January
  • CytoSorbents to Present at the 18th Annual BIO CEO & Investor Conference

    January 28, 2016
  • CytoSorbents Appoints Dr. Volker Humbert as Senior Manager of Clinical Affairs

    January 21, 2016
  • CytoSorbents 2016 – Driving Toward the Inflection Point

    January 11, 2016
  • CytoSorbents To Present at Biotech Showcase 2016

    January 4, 2016
2015
December
  • CytoSorbents Issues EAP Update

    December 21, 2015
  • CytoSorbents Expands Distribution of CytoSorb® to Vietnam

    December 15, 2015
  • CytoSorbents to Ring Opening Bell to Celebrate One Year NASDAQ Anniversary

    December 9, 2015
November
  • CytoSorbents Accelerates Growth in Q3 2015

    November 13, 2015
  • CytoSorbents To Meet With Investors at Brean Capital Life Sciences Summit and Stifel 2015 Healthcare Conference

    November 9, 2015
  • CytoSorbents to Report Q3 2015 Operating and Financial Results

    November 6, 2015
October
  • CytoSorbents To Advance HemoDefend™ Towards Commercialization with $1.5 Million Phase II SBIR Contract from NHLBI/NIH

    October 27, 2015
  • CytoSorbents Reports CytoSorb® Usage Grows to 8,000+ Human Treatments at Successful Second International Users Meeting

    October 5, 2015
September
  • CytoSorbents Ready for Second International CytoSorb® Users Meeting, ESICM and EACTS Conferences

    September 30, 2015
  • World Sepsis Day 2015: CytoSorbents Sponsors the SepsisUpdate 2015 Congress, Hugo Schottmuller Prize, and Sepsis Heroes Ceremony

    September 14, 2015
  • CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference

    September 2, 2015
August
  • CytoSorbents Reports Steady Growth in Q2 2015

    August 13, 2015
  • Saudi Food and Drug Authority Approves CytoSorb®

    August 10, 2015
  • CytoSorbents to Report Q2 2015 Operating and Financial Results

    August 6, 2015
July
  • CytoSorbents and TekMed Collaborate to Distribute CytoSorb® in Australia and New Zealand

    July 23, 2015
  • Veteran Healthcare Analyst Michael G. Bator Joins CytoSorbents Board of Directors

    July 15, 2015
June
  • CytoSorbents Corporation set to join Russell Microcap Index

    June 19, 2015
  • Privacy Information
  • Data protection
  • Disclaimer
  • contact
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.

CytoSorb® is a unique blood purification therapy.The product is currently approved in the European Union and distributed in 58 countries around the world

X
U.S. FDA Grants CytoSorb® Emergency Use Authorization for Use in Patients with COVID-19 Infection. Call 848-667-8990 to Order.